MALVERN, PA--(Marketwire - May 5, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL)
today announced that executive management will participate in the Deutsche
Bank 34th Annual
Health Care Conference to be held May 18 - May 19, 2009 at The
InterContinental Boston. Mr. Armando Anido, Chief Executive Officer and
President, is scheduled to present an overview of the Company and its
product pipeline at 11:20 a.m. EDT on Monday, May 18, 2009.

To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for ninety days after the event.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim®
1%, a topical testosterone gel, for the treatment of hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has five
projects in clinical development. XIAFLEX™ (clostridial collagenase for
injection), formerly referred to as AA4500, has completed phase III
clinical trials for the treatment of Dupuytren's contracture, is in phase
IIb of development for the treatment of Peyronie's disease and is in phase
II of development for treatment of Frozen Shoulder syndrome (Adhesive
Capsulitis). Auxilium's transmucosal film product candidate for the
treatment of overactive bladder (AA4010) is in phase I of development.
Auxilium also has one pain product (fentanyl) using its transmucosal film
delivery system in phase I of development. Auxilium has rights to
additional pain products and products for hormone replacement and urologic
disease using its transmucosal film delivery system. The Company is
currently seeking a partner to further develop these transmucosal film
product candidates. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.

Safe Harbor Statement

This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the Deutsche Bank 34th
Annual Health Care Conference, and products in development for the
treatment of Dupuytren's contracture, Peyronie's disease and Frozen
Shoulder Syndrome and for pain, hormone replacement and urologic disease.
All statements other than statements of historical facts contained in this
release, including but not limited to, statements regarding future
expectations, plans and prospects for the Company, statements regarding
forward-looking financial information and other statements containing the
words "believe," "may," "could," "will," "estimate," "continue,"
"anticipate," "intend," "should," "plan," "expect," and similar
expressions, as they relate to the Company, constitute forward-looking
statements. Actual results may differ materially from those reflected in
these forward-looking statements due to various factors, including further
evaluation of clinical data, results of clinical trials, decisions by
regulatory authorities as to whether and when to approve drug applications,
and general financial, economic, regulatory and political conditions
affecting the biotechnology and pharmaceutical industries and those
discussed in Auxilium's Annual Report on Form 10-K for the year ended
December 31, 2008 under the heading "Risk Factors," which is on file with
the Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the Internet at
http://www.Auxilium.com under the heading "Investor Relations -- SEC
Filings." There may be additional risks that Auxilium does not presently
know or that Auxilium currently believes are immaterial which could also
cause actual results to differ from those contained in the forward-looking
statements. Given these risks and uncertainties, any or all of these
forward-looking statements may prove to be incorrect. Therefore, you should
not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.